US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Enveric Biosciences

< Previous 1 2 3 Next >
News headline image
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Participation in 2025 BIO International Convention
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences CEO Issues Letter to Shareholders
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Broad Range of Patent Issuances
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
From Enveric Biosciences
Via Business Wire
Tickers ENVB
< Previous 1 2 3 Next >